Jack Higgins
Directeur Technique/Scientifique/R&D chez IMMUNOME, INC.
Fortune : - $ au 30/04/2024
Postes actifs de Jack Higgins
Sociétés | Poste | Début | Fin |
---|---|---|---|
IMMUNOME, INC. | Directeur Technique/Scientifique/R&D | 02/10/2023 | - |
Historique de carrière de Jack Higgins
Anciens postes connus de Jack Higgins
Sociétés | Poste | Début | Fin |
---|---|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Directeur Technique/Scientifique/R&D | 01/05/2022 | 01/10/2023 |
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Directeur des opérations | 22/10/2013 | 01/06/2019 |
Corporate Officer/Principal | 01/06/2019 | 01/04/2021 | |
MOLECULAR TEMPLATES, INC. | Directeur Technique/Scientifique/R&D | 01/01/2010 | - |
Formation de Jack Higgins
The University of Arkansas | Doctorate Degree |
Texas A&M University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 3 |
Chief Operating Officer | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
IMMUNOME, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Molecular Templates, Inc. /Old/
Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
- Bourse
- Insiders
- Jack Higgins
- Expérience